New Years' Resolutions

If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.

By Kate Rawson

The coming year will bring Food & Drug Administration approval of a first-ever cancer vaccine, the reintroduction of a withdrawn...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Agency Leadership

More from Pink Sheet

Merck’s Keytruda Gains Medicare Negotiation Reprieve With Expanded Orphan Exemption

 
• By 

Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

 

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines

 

US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.